Tuesday, April 11, 2023
Veneno Technologies Co. Ltd. is pleased to announce that we have entered into a joint research agreement with Astellas Pharma Inc. ("Astellas")
Under the terms of the agreement, Veneno [https://veneno.jp/] will conduct a program to obtain functional peptides (DRPs) for G protein-coupled receptors (GPCRs) targeted by Astellas using our next-generation peptide discovery technology, the PERISS method (intra-periplasm secretion and selection). Work on this project is expected to begin during the 1st Quarter, 2023.
Source: prnewswire.com
